Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Cost of Revenue data on file, last reported at $298.3 million in Q2 2026.

• Quarterly Cost of Revenue rose 110.0% year-over-year to $298.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $970.7 million (up 144.62% YoY) and the FY2025 annual result came in at $677.2 million, up 120.93% from the prior year.
• Cost of Revenue advanced to $298.3 million in Q2 2026, from $207.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $298.3 million in Q2 2026 to a low of $23.5 million in Q1 2022.
• A 5-year average of $105.4 million and a median of $73.7 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue slipped 10.71% — and 2026, when it soared 195.68%.
• Tracing ALNY's Cost of Revenue over 5 years: stood at $46.2 million in 2022, then surged by 55.88% to $72.0 million in 2023, then soared by 42.62% to $102.6 million in 2024, then jumped by 160.81% to $267.7 million in 2025, then gained by 11.41% to $298.3 million in 2026.
• The last three Cost of Revenue figures came in at $298.3 million (Q2 2026), $207.5 million (Q1 2026), and $267.7 million (Q4 2025), per Business Quant data.